Tuberculosis Therapeutics Market

Tuberculosis Therapeutics Market Overview (2022 to 2032)

The global tuberculosis therapeutics market was valued at around US$ 1.1 Billion at the end of 2021. The market is projected to register a 7.1% CAGR and top a valuation of US$ 2.3 Billion by 2032.

The rising prevalence of tuberculosis, and the rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing countries are likely to encourage the tuberculosis therapeutics market growth.

An infectious disease called tuberculosis (TB) is typically brought on by the bacteria called Mycobacterium tuberculosis (MTB). Although TB often affects the lungs, other body parts are also susceptible to tuberculosis. Latent TB is the term used when an infection does not show any symptoms. 10% of latent infections develop into active disease, which, if untreated, kills around 50% of individuals who are infected. Blood with mucus in the cough, fever, nocturnal sweats, and loss of weight are all signs of active TB.

Isoniazid INH in combination with rifampin, pyrazinamide, and ethambutol is the most widely used treatment for active Tuberculosis.

Attributes	Details
Tuberculosis Therapeutics Market Value in 2021	US$ 1.1 Billion
Tuberculosis Therapeutics Market Value in 2032	US$ 2.3 Billion
Tuberculosis Therapeutics Market CAGR (2022 to 2032)	7.1%

What are the Major Drivers Boosting the Demand for Tuberculosis Therapeutics Market?

Tuberculosis is one of the top 10 causes of death worldwide. Leading medical regulatory authorities are challenged by the prevalence of tuberculosis around the world. It is anticipated that there would be an increase in tuberculosis diagnoses as a result of the government's and medical community's strong involvement in the prevention of this disease. Thus, this will expand the global tuberculosis therapeutics market.

The market for tuberculosis therapeutics is expected to grow as the elderly population increases. Due to their weakened immune systems, older individuals are more susceptible to both chronic and acute diseases. Due to the immune system-weakening effects of several medications, such as chemotherapy and those used to treat arthritis and psoriasis, tuberculosis risk is increased.

Additionally, the market for tuberculosis therapeutics will grow as a result of increased awareness-raising efforts by both governmental and private organizations. The market for tuberculosis therapeutics will also grow as a result of people's changing lifestyles, an increase in instances of MDR-TB and XDR-TB in developing nations, and changing consumer preferences.

Which Region Shows Strong Growth Potential in the Tuberculosis Therapeutics Market?

North America holds the major chunk of the global tuberculosis therapeutics market. Due to the existence of well-established key players, growing cases of tuberculosis in the region, and increased healthcare spending.

Due to the presence of a large geriatric population suffering from chronic diseases, Europe is predicted to have the fastest-growing demand for tuberculosis therapeutics.

East Asia is expected to grow lucratively during the course of the forecast period as a result of the rising number of generic manufacturers, and expansion of healthcare infrastructure.

Who are the Key Players in the Tuberculosis Therapeutics Market?

AstraZeneca PLC, Eli Lilly, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Lupin Ltd., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Panacea Biotec Ltd., Pfizer, Inc., Sanofi, Novartis AG, Sun Pharmaceuticals Industries Ltd.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 7.1% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Billion, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Disease Type Treatment Type Diagnosis Dosage Form End User Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany UK France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline PLC Johnson & Johnson Lupin Ltd. Merck & Co., Inc. Otsuka Pharmaceutical Co., Ltd. Panacea Biotec Ltd. Pfizer, Inc. Sanofi Novartis AG SunPharmaceuticals Industries Ltd.
Customization	Available Upon Request

Key Segments Covered in the Tuberculosis Therapeutics Industry Survey

By Disease Type:

• Active TB
• Latent TB

By Treatment Type:

• First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
• Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
• Others

By Diagnosis:

• Blood Tests
• Imaging Tests
  • Chest X-ray
  • CT scan
• Sputum Tests
• Others

By Dosage Form:

• Tablets
• Capsules
• Injections
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

What is the Growth Outlook for the Global Tuberculosis Therapeutics Market?

The global tuberculosis therapeutics market is anticipated to register a CAGR of 7.1% during the forecast period.

Who are the Key Players in the Tuberculosis Therapeutics Market?

The top players in the global tuberculosis therapeutics market are AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Lupin Ltd., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Panacea Biotec Ltd., Pfizer, Inc., Sanofi, Novartis AG, Sun Pharmaceuticals Industries Ltd.